Rhea-AI Summary
Panbela Therapeutics, a biopharmaceutical company, announces the acceptance of an abstract on eflornithine for oral presentation at the Digestive Disease Week. The presentation focuses on the safety and efficacy of eflornithine in patients with gastric premalignant conditions in Latin America. The conference will take place on May 18-21, 2024, showcasing the Company's collaboration with Vanderbilt University Medical Center.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.05%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.44%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.35%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.46%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-65.34%
Tags
FAQ
What is the current stock price of PANBELA THERAPEUTICS (PBLA)?
The current stock price of PANBELA THERAPEUTICS (PBLA) is $0.000001 as of October 2, 2026.
What is the market cap of PANBELA THERAPEUTICS (PBLA)?
The market cap of PANBELA THERAPEUTICS (PBLA) is approximately 242.7K.